Regeneron Pharmaceuticals Inc. and Sanofi-Aventis U.S. failed to convince a federal judge to toss a lawsuit alleging they failed to provide adequate warnings about about potentially fatal side effects of skin cancer drug Libtayo.
Plaintiffs on behalf of a woman who died from Stevens-Johnson Syndrome and toxic epidermal necrolysis caused by Libtayo adequately alleged the drug’s label failed to warn doctors of the risks of those conditions, Judge Wesley L. Hsu of the US District Court for the Central District of California said April 24.
The plaintiffs alleged six inadequacies with the drug’s label including that Libtayo can cause SJS ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.